Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of brain tumour — either a grade 4 glioblastoma (GBM) with a particular genetic profile (IDH-wildtype), or a grade 3 astrocytoma with certain genetic markers — classified according to the 2021 World Health Organization system.
- People who have already completed a standard course of radiation therapy to the brain.
- For GBM patients: people who received at least 80% of their planned daily doses of the chemotherapy drug temozolomide (TMZ) during radiation treatment. For astrocytoma patients: people who completed at least 2 but no more than 4 cycles of TMZ after radiation.
- People whose blood counts and organ function (including kidneys, liver, and blood) are within acceptable ranges based on lab tests.
- People who are willing to either avoid sexual intercourse or use an approved form of contraception during the trial.
- People taking steroid medications, provided the dose is stable or being reduced at the time of joining.
Who may not be able to join:
- People with a recent history of another cancer that has come back or spread to other parts of the body, which could make it harder to assess how the brain tumour is responding to treatment.
- People who have previously received any cancer chemotherapy other than temozolomide (as described above for each tumour type).
- People who have previously used a device called Optune (a wearable tumour treatment device).
- People who have an active infection or another serious ongoing medical condition.
- People whose seizures are not well controlled.
- People who have had a significant heart condition within the 6 months before joining the trial.
- People whose diabetes is not well controlled.
- People who have taken part in another clinical trial or used an experimental treatment within 30 days before joining this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Howard Colman, MD, PhD, Huntsman Cancer Institute/ University of Utah
Phone: 6506569424
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of Dose Limiting Toxicities; Incidence of TEAEs All Grades; Incidence of TEAEs Grade 3+; Incidence of TEAEs Serious; Incidence of TEAEs Leading to Discontinuation; Vital Signs (Heart and Respiratory Rate); Vital Signs (Blood Pressure); Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.